When choosing statin therapy: The case for generics

JAMA Internal Medicine

Volumn 173, Issue 3, 2013, Pages 229-232

  Green, Jonas B ^a   Ross, Joseph S ^b,e,f   Jackevicius, Cynthia A ^g,h   Shah, Nilay D ⁱ   Krumholz, Harlan M ^c,d,e,f  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Sections of General Internal Medicine   (United States)

^c Cardiovascular Medicine   (United States)

^d Section of Health Policy and Administration   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f YALE NEW HAVEN HOSPITAL   (United States)

^g WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; COMPACTIN; FLUINDOSTATIN; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

CARDIOVASCULAR RISK; DRUG EFFICACY; DYSLIPIDEMIA; HUMAN; PRIORITY JOURNAL; REVIEW;

CARDIOVASCULAR DISEASES; CHOICE BEHAVIOR; DRUGS, GENERIC; DYSLIPIDEMIAS; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; THERAPEUTIC EQUIVALENCY;

EID: 84874072096     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.1529     Document Type: Review

References (31)

1. Good Stewardship Working Group. The "top 5" lists in primary care: Meeting the responsibility of professionalism. Arch Intern Med. 2011;171 (15):1385-1390.
2. Shepherd J, Cobbe SM, Ford I, et al West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333(20):1301-1307.
3. Pedersen TR, Tobert JA. Benefits and risks of HMGCoA reductase inhibitors in the prevention of coronary heart disease: A reappraisal. Drug Saf. 1996; 14(1):11-24.
4. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA. 1999;282(24): 2340-2346.
5. Smith MEB, Lee NJ, Haney E, Carson S. Drug Class Review: HMG-CoA Reductase Inhibitors (Statins) and Fixed-Dose Combination Products Containing a Statin: Final Report Update 5. Portland: Oregon Health & Science University; 2009.
6. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA. 1998;279: 1643-1650.
7. Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: A comparative metaanalysis of randomised controlled trials. Heart. 2007;93(8):914-921.
8. Baigent C, Blackwell L, Emberson J, et al Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681.
9. Pedersen TR, Faergeman O, Kastelein JJ, et al Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial. JAMA. 2005;294(19):2437-2445.
10. Deedwania P, Stone PH, Bairey Merz CN, et al. Effects of intensive versus moderate lipidlowering therapy on myocardial ischemia in older patients with coronary heart disease: Results of the Study Assessing Goals in the Elderly (SAGE). Circulation. 2007;115(6):700-707.
11. Cannon CP, Braunwald E, McCabe CH, et al Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495-1504.
12. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011; 365(22):2078-2087.
13. Boden WE, Probstfield JL, Anderson T, et al AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24): 2255-2267.
14. Ginsberg HN, Elam MB, Lovato LC, et al ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17):1563-1574.
15. Rossebø AB, Pedersen TR, Boman K, et al SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359(13):1343-1356.
16. Sharma M, Ansari MT, Soares-Weiser K, et al. Comparative Effectiveness of Lipid-Modifying Agents. Rockville, MD: Agency for Healthcare Research and Quality; 2009.
17. Shrank WH, Hoang T, Ettner SL, et al. The implications of choice: Prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med. 2006;166(3):332-337.
18. Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S. Optimizing statin treatment for primary prevention of coronary artery disease. Ann Intern Med. 2010;152(2):69-77.
19. Medco Health Solutions Inc. Drug Trend Report. Vol 9. Franklin Lakes, NJ: Medco Health Solutions Inc; 2007.
20. Top 200 drugs by sales [annual]. Drugs.com website. http://www.drugs.com/ top200-units.html. Accessed October 18, 2011.
21. Gury M. IMS reports 12 percent growth in 2001 audited global pharmaceutical sales to $364 billion [press release]. IMS Health website. 2002.http://www.imshealth.com. Accessed September 25, 2011.
22. Maggon K. Best-selling human medicines 2002-2004. Drug Discov Today. 2005;10(11): 739-742.
23. IMS Institute for Healthcare Informatics. The Use of Medicines in the United States: Review of 2010.
24. Parsippany, NJ: IMS Institute for Healthcare Informatics; 2011.
25. Jack A. The fall of the world's best-selling drug. Financial Times website. 2009. http://www.ft.com/intl/cms/s/0/d0f7af5c-d7e6-11de-b578- 00144feabdc0.html#axzz20TeYOEAX. Accessed September 25, 2011.
26. Larkin C. Lipitor Topped Worldwide Drug Sales in 2010; Crestor Gains Most. Bloomberg website. 2011. http://www.bloomberg.com/news/2011-02-10/lipitor- topped-worldwide-drug-sales-in-2010-crestor-gains-most.html. Accessed January 17, 2012.
27. Kale MS, Bishop TF, Federman AD, Keyhani S. "Top 5" lists top $5 billion. Arch Intern Med. 2011; 171(20):1856-1858.
28. Shrank WH, Cox ER, Fischer MA, Mehta J, Choudhry NK. Patients' perceptions of generic medications. Health Aff (Millwood). 2009;28 (2):546-556.
29. Shrank WH, Cadarette SM, Cox E, et al. Is there a relationship between patient beliefs or communication about generic drugs and medication utilization? Med Care. 2009;47(3):319-325.
30. Shrank WH, Liberman JN, Fischer MA, Girdish C, Brennan TA, Choudhry NK. Physician perceptions about generic drugs. Ann Pharmacother. 2011;45(1):31-38.
31. Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: A systematic review and meta-analysis. JAMA. 2008;300:2514-2526.